Prime Highlights
- Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics in a deal valued at more than $2 billion, according to media reports.
- The potential acquisition is expected to strengthen Lilly’s presence in cancer treatment and genetic medicine.
Key Facts
- Kelonia Therapeutics is a Boston-based clinical-stage biotech company focused on genetic medicines and CAR-T cell therapies.
- Lilly’s oncology portfolio already includes therapies such as Jaypirca and Verzenio, and the deal would further expand its cancer pipeline.
Background
Eli Lilly is in advanced discussions to acquire biotechnology firm Kelonia Therapeutics in a deal valued at more than $2 billion, a move that could significantly expand the drugmaker’s presence in cancer treatment and genetic medicine. A final agreement could be reached as early as this week, according to media reports.
The proposed transaction may also include additional milestone-based payments linked to Kelonia’s clinical and commercial progress. Neither company has publicly confirmed the terms of the potential deal.
Boston-based Kelonia is a clinical-stage biotech company focused on developing genetic medicines, with particular emphasis on CAR-T cell therapies, an advanced treatment approach that engineers a patient’s immune cells to identify and attack cancer cells. The technology has emerged as an important area in oncology, especially for blood cancers.
If completed, the acquisition would strengthen Lilly’s oncology portfolio, which already includes therapies such as Jaypirca and Verzenio. The deal would also support the company’s broader strategy of expanding beyond its highly successful weight-loss and diabetes drug business into other high-growth therapeutic areas.
Lilly has been making acquisitions and partnerships to expand its pipeline in cancer, inflammatory diseases, eye disorders and gene-editing technologies. Earlier this year, the company announced another major biotech deal as it continued to strengthen its drug development pipeline.
The potential Kelonia deal underlines Lilly’s long-term growth plans through strategic deals in advanced medicine and cancer research.
